Remove 2005 Remove Biosimilars Remove International
article thumbnail

Organon Announces Proposed Senior Notes Offering

The Pharma Data

Led by the growing reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in future growth opportunities in women’s health.

article thumbnail

Organon Announces Pricing of Senior Notes Offering

The Pharma Data

Led by the growing reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in future growth opportunities in women’s health.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Tezepelumab NAVIGATOR Phase 3 Trial Met Primary Endpoint Of A Statistically Significant And Clinically Meaningful Reduction In Exacerbations In A Broad Population Of Patients With Severe Asthma

The Pharma Data

Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. J Intern Med 2012;272:121–32. 2005; 172; 149–60. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Last accessed: September 2020 ]. 6 Kupczyk M, Wenzel S. 7 Wenzel S.

Trials 52
article thumbnail

Amgen Announces Pricing Terms For Senior Notes Exchange Offers, Increases The Maximum Notes Exchange Cap And Accepts Tendered Notes

The Pharma Data

Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities.

article thumbnail

Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma

The Pharma Data

Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. 2005; 172: 149-160. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. 2019;12(5):539-549. Wenzel S. Severe asthma in adults. Am J Respir Crit Care Med.

Trials 40
article thumbnail

Amgen Announces Early Tender Results Of Senior Notes Exchange Offers

The Pharma Data

Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities.

article thumbnail

FDA’s Proposal to Remove Oral Phenylephrine from the OTC Monograph Isn’t a Surprise but What is Left “Over-the-Counter”?

FDA Law Blog: Biosimilars

As those of us of a certain age remember, prior to 2005/2006, pseudoephedrine was the decongestant of choice for OTC multi-symptom cold medicine. Then, Congress passed, and the President signed the Combat Methamphetamine Epidemic Act of 2005. a); OTC Monograph M012: § M012.20. a); OTC Monograph M012: § M012.20.

FDA 111